| Primary |
| Pancreatic Carcinoma |
23.0% |
| Non-small Cell Lung Cancer |
10.5% |
| Pancreatic Carcinoma Stage Iv |
6.6% |
| Prophylaxis |
6.6% |
| Breast Cancer Metastatic |
5.5% |
| Bile Duct Cancer |
5.0% |
| Lung Neoplasm Malignant |
4.9% |
| Bladder Cancer |
4.3% |
| Ovarian Cancer |
4.0% |
| Hypertension |
3.6% |
| Pancreatic Carcinoma Metastatic |
3.6% |
| Pain |
3.6% |
| Prophylaxis Of Nausea And Vomiting |
3.2% |
| Adenocarcinoma Pancreas |
2.9% |
| Breast Cancer |
2.7% |
| Constipation |
2.1% |
| Cancer Pain |
2.0% |
| Premedication |
1.9% |
| Transitional Cell Carcinoma |
1.9% |
| Ovarian Cancer Recurrent |
1.9% |
|
| Death |
16.2% |
| White Blood Cell Count Decreased |
9.5% |
| Thrombocytopenia |
8.3% |
| Malignant Neoplasm Progression |
7.9% |
| Vomiting |
7.5% |
| Pyrexia |
6.1% |
| Interstitial Lung Disease |
4.9% |
| Platelet Count Decreased |
3.6% |
| Neoplasm Progression |
3.6% |
| Pleural Effusion |
3.6% |
| Lung Disorder |
3.2% |
| Pneumonia |
3.2% |
| Off Label Use |
3.1% |
| Renal Failure |
3.0% |
| Pulmonary Embolism |
3.0% |
| Thrombotic Thrombocytopenic Purpura |
2.8% |
| Sepsis |
2.8% |
| Thrombotic Microangiopathy |
2.8% |
| Haematotoxicity |
2.7% |
| Pulmonary Toxicity |
2.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
16.3% |
| Product Used For Unknown Indication |
14.6% |
| Non-small Cell Lung Cancer |
14.4% |
| Pancreatic Carcinoma |
8.7% |
| Prophylaxis |
7.4% |
| Breast Cancer Metastatic |
4.2% |
| Pancreatic Carcinoma Stage Iv |
4.1% |
| Breast Cancer |
4.1% |
| Hypertension |
3.0% |
| Adenocarcinoma Pancreas |
2.9% |
| Premedication |
2.8% |
| Pain |
2.3% |
| Lung Neoplasm Malignant |
2.3% |
| Bile Duct Cancer |
2.1% |
| Pancreatic Carcinoma Metastatic |
2.0% |
| Prophylaxis Of Nausea And Vomiting |
2.0% |
| Lung Adenocarcinoma |
1.8% |
| Constipation |
1.8% |
| Cancer Pain |
1.7% |
| Ovarian Cancer |
1.5% |
|
| White Blood Cell Count Decreased |
15.0% |
| Thrombocytopenia |
10.7% |
| Vomiting |
10.1% |
| Interstitial Lung Disease |
7.1% |
| Malignant Neoplasm Progression |
6.7% |
| Pyrexia |
6.0% |
| Pulmonary Embolism |
5.3% |
| Platelet Count Decreased |
4.0% |
| Sepsis |
3.7% |
| Urinary Tract Infection |
3.6% |
| Death |
3.3% |
| Pleural Effusion |
3.2% |
| Renal Failure Chronic |
3.1% |
| Weight Decreased |
2.9% |
| C-reactive Protein Increased |
2.8% |
| Pancreatic Carcinoma |
2.7% |
| Rash |
2.7% |
| Anaemia |
2.4% |
| Neutrophil Count Decreased |
2.4% |
| Renal Failure Acute |
2.3% |
|
| Concomitant |
| Breast Cancer |
12.9% |
| Product Used For Unknown Indication |
12.8% |
| Metastases To Bone |
12.1% |
| Breast Cancer Metastatic |
11.0% |
| Drug Use For Unknown Indication |
6.0% |
| Pancreatic Carcinoma |
4.9% |
| Chemotherapy |
4.3% |
| Pain |
4.1% |
| Prophylaxis |
4.0% |
| Nausea |
3.5% |
| Non-small Cell Lung Cancer |
3.4% |
| Depression |
3.1% |
| Premedication |
2.9% |
| Ovarian Cancer |
2.8% |
| Cancer Pain |
2.5% |
| Lung Neoplasm Malignant |
2.4% |
| Hypercalcaemia |
2.4% |
| Lung Adenocarcinoma |
1.7% |
| Muscle Spasms |
1.7% |
| Diabetes Mellitus |
1.6% |
|
| Death |
11.3% |
| Weight Decreased |
10.8% |
| Vomiting |
9.2% |
| Tooth Extraction |
8.8% |
| Toothache |
7.0% |
| Disease Progression |
5.6% |
| Wheezing |
5.3% |
| Thrombocytopenia |
5.1% |
| Metastases To Liver |
4.5% |
| Rash |
4.0% |
| Wound Infection Staphylococcal |
3.8% |
| Osteonecrosis |
3.3% |
| White Blood Cell Count Decreased |
3.0% |
| Pyrexia |
2.9% |
| Pain |
2.7% |
| Pneumonia |
2.7% |
| Drug Ineffective |
2.5% |
| Tooth Loss |
2.5% |
| Weight Increased |
2.5% |
| Platelet Count Decreased |
2.4% |
|
| Interacting |
| Metabolic Syndrome |
41.7% |
| Bile Duct Cancer |
12.6% |
| Pancreatic Carcinoma |
10.9% |
| Prophylaxis |
10.3% |
| Arthritis |
9.1% |
| Non-small Cell Lung Cancer |
5.7% |
| Essential Thrombocythaemia |
4.0% |
| Gout |
3.4% |
| Ovarian Epithelial Cancer |
1.7% |
| Cholangitis |
0.6% |
|
| Rhabdomyolysis |
25.0% |
| Weight Increased |
22.5% |
| Sepsis |
15.0% |
| Pancytopenia |
12.5% |
| Drug Interaction |
10.0% |
| Rash Erythematous |
10.0% |
| Renal Failure Acute |
5.0% |
|
